Lokelma(sodium zirconium cyclosilicate)
Lokelma (sodium zirconium cyclosilicate) is a small molecule pharmaceutical. Sodium zirconium cyclosilicate was first approved as Lokelma on 2018-03-22. It is used to treat hyperkalemia in the USA. It has been approved in Europe to treat hyperkalemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Lokelma
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sodium zirconium cyclosilicate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LOKELMA | AstraZeneca | N-207078 RX | 2018-05-18 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lokelma | New Drug Application | 2024-02-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyperkalemia | HP_0002153 | D006947 | E87.5 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SODIUM ZIRCONIUM CYCLOSILICATE, LOKELMA, ASTRAZENECA | |||
| 2023-05-18 | NCE | ||
| 2023-04-24 | M-261 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Sodium Zirconium Cyclosilicate, Lokelma, Astrazeneca | |||
| 9592253 | 2035-10-14 | DP | U-2312 |
| 10300087 | 2035-10-14 | DP | U-2312 |
| 8877255 | 2033-10-22 | DP | |
| 9913860 | 2033-10-22 | DP | U-2312 |
| 10695365 | 2033-10-22 | DP | |
| 8802152 | 2032-04-19 | DP | |
| 8808750 | 2032-02-10 | U-2312 | |
| 9844567 | 2032-02-10 | U-2312 | |
| 9861658 | 2032-02-10 | U-2312 | |
| 10335432 | 2032-02-10 | U-2312 | |
| 10398730 | 2032-02-10 | U-2312 | |
| 10413569 | 2032-02-10 | DP | |
| 11406662 | 2032-02-10 | DP | |
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperkalemia | D006947 | HP_0002153 | E87.5 | 3 | 5 | 15 | 7 | 6 | 35 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | 1 | 5 | 2 | 3 | 12 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | 4 | 2 | 3 | 11 |
| Heart failure | D006333 | HP_0001635 | I50 | — | 2 | 2 | 1 | 1 | 6 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | 1 | — | 2 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | — | — | 1 | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | 1 | — | 1 |
| Diet therapy | D004035 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | 1 | — | — | 2 |
| Acidosis | D000138 | EFO_1000014 | E87.2 | — | — | 1 | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | 1 | — | — | 1 |
| Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sodium zirconium cyclosilicate |
| INN | — |
| Description | Sodium zirconium cyclosilicate, sold under the brand name Lokelma, is a medication used to treat high blood potassium. Onset of effects occurs in one to six hours. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 242800-27-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301592 |
| ChEBI ID | — |
| PubChem CID | 91799284 |
| DrugBank | DB14048 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Lokelma – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 631 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,329 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use